Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Acute kidney injury (AKI) is common in critically ill patients, and continuous renal replacement therapy (CRRT) is often indicated in those with hemodynamic instability. Vancomycin requires close therapeutic drug monitoring to achieve target plasma concentrations while minimizing toxicity. The objective of this preliminary analysis was to evaluate the proportion of CRRT patients achieving vancomycin plasma levels >20 mg/L at 24 and 48 hours of treatment.
Adult critically ill patients receiving concurrent vancomycin therapy and CRRT at the University Hospital “Dr. José Eleuterio González” from June 2025 were included. Vancomycin concentrations were measured in serum and effluent at 24 and 48 hours using the ARCHITECT iVancomycin assay. To date, four of eleven planned patients have been analyzed.
The sample included young and middle-aged adults (mean age 37 years) with balanced sex distribution and wide BMI variability, ranging from normal weight to severe obesity. Most patients had advanced kidney disease (75% chronic kidney disease), while some presented with severe AKI (KDIGO3), reprsenting a mixed renal impairment profile. Cardiac function was impaired in several patients (mean LVEF 41%), and severity scores were high (median SOFA 15, median APACHE II 16.5, mean SAPS3 58.75), indicating moderate-to-high mortality risk.
Continuous CRRT was applied consistently, with median doses of 22.75 ml/kg/h and a median filter duration of 72 hours. Vancomycin pharmacokinetics showed marked interindividual variability in both serum and effluent levels at 24 and 48 hours, reflecting differences in drug clearance despite similar CRRT dosing.
These findings highlight the need for individualized therapeutic monitoring of vancomycin in critically ill patients undergoing CRRT to optimize antimicrobial efficacy and minimize toxicity. Compared with international reports, patients in this series showed higher initial serum concentrations and wide variability in vancomycin clearance, even under similar CRRT doses, suggesting potential pharmacokinetic differences related to physiological and technical factors specific to this population. Moreover, data on vancomycin management and pharmacokinetics in Mexican patients undergoing CRRT are extremely limited; therefore, this preliminary analysis provides a relevant and necessary contribution to contextualize dosing and monitoring strategies within our clinical setting.
